Monique L. Mounce: At the time of research, Monique Mounce was a Postgraduate Year 2 Pharmacotherapy Resident at Philadelphia College of Pharmacy and Cooper University Hospital. She completed the manuscript writing and submission as an Assistant Professor at the Notre Dame of Maryland University School of Pharmacy.
To view enhanced content for this article go to http://www.medengine.com/Redeem/57FBF06046C64311.
Integrase strand transfer inhibitors (INSTI) are currently being investigated for the treatment of HIV in pregnancy. The purpose of this study is to evaluate the differences in maternal and infant outcomes in HIV-positive mothers treated with INSTI-containing antiretroviral therapy (ART) during pregnancy compared to protease inhibitor (PI)-containing ART.
A retrospective, cohort study of INSTI- and PI-based ART used in pregnancy between 2007 and 2015 was performed. The primary objective was to evaluate the differences in viral load (VL) suppression prior to delivery. Secondary endpoints included time to and duration of VL suppression and safety parameters in both mothers and infants. For the primary analysis, the two arms were matched 1:2 INSTI to PI based on the presence or absence of viremia at the time of pregnancy determination. Additional analysis was performed on the entire matched and unmatched dataset.
Twenty-one patients were matched (7 INSTI and 14 PI). There were no significant differences between groups with respect to the proportion of patients with VL suppression prior to delivery (71.4% INSTI vs. 92.9% PI, p = 0.247), and there were no significant differences in any of the secondary endpoints. Patients with documented adherence issues were statistically more likely to not be virologically suppressed prior to delivery (p = 0.002).
No differences in efficacy or safety were found between patients treated with INSTIs compared to PIs. This study supports the further investigation of the use of INSTIs during pregnancy to reduce HIV transmission.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 30 May 2017.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Assessed May 2017.
Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011;7:CD003510.
Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection—United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2005;55(21):592–7.
Markowitz M, Morales-Ramirez JO, Nguyen B-Y, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509–15. CrossRefPubMed
Trahan MJ, Lamarre V, Metras ME, et al. Raltegravir for prevention of mother-to-child transmission of HIV. Oral presentation at: 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2015 Jul 19–22; Vancouver, Canada. Abstract TUAB0105.
Brites C, Nobrega I, Travassos AG, et al. Raltegravir vs. lopinavir/r for late-presenters pregnant women. Oral presentation at: 9th International AIDS Society Conference on HIV Science; 2017 Jul 23–26; Paris, France. Oral Abstract WEAC0201.
Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 Jan 2017. Wilmington, NC: Registry Coordinating Center. http://www.APRegistry.com. Assessed May 2017.
Mulligan N, Best BM, Capparelli E, et al. Dolutegravir pharmacokinetics in HIV-infected pregnant and postpartum women. Poster presented at: Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25; Boston, MA Abstract 438.
Isentress [Package insert]. Merck Sharp & Dohme, Corp. Whitehouse Station, NJ. 2014. http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf.
Tivicay [Package insert]. GlaxoSmithKline. Research Triangle Park, NC. Aug 2015. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF.
Best BM, Capparelli E, Stek A, et al. Elvitegravir/cobicistat pharmacokinetics in pregnancy and postpartum. Poster presented at: Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle, WA. Abstract 755.
- A Single-Center Retrospective Cohort Analysis of Maternal and Infant Outcomes in HIV-Infected Mothers Treated with Integrase Inhibitors During Pregnancy
Monique L. Mounce
Jessica L. Adams
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II